VoterVoice Post

New Ethical Shingles Vaccine – Say Thank you!

July 16, 2018 by Jeff Caruso

Please take a moment to thank GSK for developing a new shingles vaccine without using fetal cell lines from abortions.

The FDA recently approved a new shingles vaccine that does not use aborted fetal cell lines, and has given it a preferential recommendation over the only other available, and morally problematic, shingles vaccine on the market. The vaccine was developed by the health care company GlaxoSmithKline (GSK).

Please take a moment to send a thank-you letter!

The sample letter linked above, provided by the U.S. Conference of Catholic Bishops, can be mailed to GSK. The letter can also be found at the bottom of this email.

By thanking GSK, we hope to encourage them to develop more morally acceptable vaccines.

The only vaccines readily available in the United States for some contagious diseases (e.g., rubella and Hepatitis A) have been manufactured using fetal tissue from induced abortions. This creates a problem of conscience for some Catholic parents. Let’s show that there is a market demand for morally acceptable alternatives!

Thank you for your advocacy!
Sample letter:
Thank-You Letter to GlaxoSmithKline from individual Catholics
Patrick Desbiens Senior Vice President
GSK US Vaccines
5 Crescent Drive
Philadelphia, PA 19112
Dear Mr. Desbiens,
I write to thank you and your colleagues at GlaxoSmithKline for the development of your new shingles vaccine, Shingrix.  I am grateful because I learned that your new vaccine was not derived from cell lines linked to elective abortion, and I intend to share this good news with my friends and family.
As you are probably aware, many Catholics do not wish to use vaccines or medicines produced from cell lines linked to elective abortion.  Shingrix will most certainly alleviate those concerns and I hope that our use and promotion of this vaccine will provide GSK with an incentive to pursue other vaccines and medicines that have no connection to elective abortion.
Again, I commend you for your efforts and look forward to sharing this good news.